Navigation Links
Favrille Announces Resolution of Debt Obligations and Plans for Maximizing Assets
Date:7/7/2008

cility and other assets over the past few weeks," said John P. Longenecker, Ph.D., President and Chief Executive Officer of Favrille. "The future direction of the Company going forward remains uncertain but could include either a reorganization which might involve in-licensing of products contingent upon additional financing, a merger with another entity or liquidation of the Company either inside or outside of bankruptcy. We will continue to explore the relative benefits of all these options. The management and board of directors of Favrille remain committed to addressing these issues and maximizing the value of our assets as expeditiously as possible."

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system.

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Favrille's product candidates, proprietary technologies and research and clinical development programs. Such forward- looking statements involve known and unknown risks, uncertainties and other factors that may cause Favrille's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to Favrille's ability to continue its operations, conserve cash or recognize value on our assets and additional risks discussed in Favrille's filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement. Favrille is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements containe
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
2. Favrille CEO to Present at Bear Stearns Healthcare Conference
3. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
4. Favrille to Present at BIO InvestorForum
5. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
6. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
7. Favrille Announces $21.1 Million Registered Direct Offering
8. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
9. Favrille to Host Conference Call and Live Webcast to Discuss First Quarter 2008 Financial Results on May 8, 2008
10. Favrille Reports First Quarter 2008 Financial Results
11. Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... CIO Review ( http://www.cioreview.com ) has chosen ... Pharma and Life Science Technology Solution Providers 2015. The ... platform for life sciences companies. , The annual ... experts and members of CIO Review’s editorial board to ... been on our radar for some time now for ...
(Date:4/17/2015)... , April 17, 2015  US-Australian drug discovery company, ... Memorandum of Understanding with the Feinstein Institute for ... York to collaborate with the objective ... The collaboration brings together the drug discovery ... expertise of the Feinstein Institute in neurosciences and ...
(Date:4/17/2015)... WI (PRWEB) April 17, 2015 ... sales and marketing support for the powerful Orthogonal ... the Chemical Genomics Center at the Lankenau Institute ... LCGC’s mission is to measurably improve successful drug ... HTS, by offering rare, drug-like libraries available nowhere ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 ... data solutions driven by Semantic Web technology, and ... specialist information and services for the academic and ... that its joint solution ‘Smart Data Lake for ... finalist for the 2015 Bio-IT ‘Best of Show’ ...
Breaking Biology Technology:MMIS Chosen by CIO Review as Top 20 Most Promising Pharma and Life Science Technology Solution Providers 2015 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 4Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 5Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 6BellBrook Labs and Lankenau Institute Partner to Accelerate Drug Discovery using Orthogonal Pooled Screening 2Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 2Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 3
... 27 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,(ASX: PXS, Nasdaq: PXSL) ... included as an approved test by the ... approval was contained in their just-released IOC ... athletes competing in the,Beijing Olympics. The prevalence ...
... BERKELEY HEIGHTS, N.J., March 27 Genta,Incorporated (Nasdaq: ... Panel has granted the Company,s request for an ... applicable NASDAQ listing,requirements. Pursuant to the Panel,s decision, ... transferred from The NASDAQ Global Market to,The NASDAQ ...
... March 27 PAREXEL International,Corporation ("PAREXEL") (Nasdaq: ... minority interest ownership in the clinical pharmacology business ... announced the sale,of a bioanalytical laboratory in Poitiers, ... Under the terms of the new agreement, ...
Cached Biology Technology:Aridol(TM) Endorsed by International Olympic Committee 2Aridol(TM) Endorsed by International Olympic Committee 3Aridol(TM) Endorsed by International Olympic Committee 4Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements 2Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements 3PAREXEL International Expands Relationship with Synchron Research in India and Divests Bioanalytical Laboratory in France 2PAREXEL International Expands Relationship with Synchron Research in India and Divests Bioanalytical Laboratory in France 3PAREXEL International Expands Relationship with Synchron Research in India and Divests Bioanalytical Laboratory in France 4
(Date:3/19/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, announces its biometric payment technology, the Wocket® ... this week on Washington DC,s Fox ... segment "The Next Great Thing", host Laura Evans ... and ,a really big breakthrough in mobile payment.,  ...
(Date:3/17/2015)... MINNETONKA, Minn. , March 17, 2015 /PRNewswire/ ... sciences technology company specializing in clinical study management ... will be in attendance at ARENA,s Outsourcing in ... Cary, NC.  This event provides an excellent forum ... company,s easy-to-use, flexible and affordable software-as-a-service (SaaS) eClinical ...
(Date:3/17/2015)... , March 17, 2015  MecklerMedia Corporation ... largest exhibition for service robots ever held in ... takes place on May 11-13, 2015 at the ... exhibitors for the event include: Acorn Product Development; ... EZ-Robot; Infranor; Kinova Robotics; Littler; NewBotic Corporation; Neya ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
... -- Spectacularly increased yields and improved taste have been ... Robert H. Smith Faculty of Agriculture, Food and Environment ... Laboratory (CSHL), New York. The researchers have discovered ... when plants make flowers and that works in different ...
... Using CT scans to measure blood flow in the ... identify which smokers are most at risk of emphysema before ... according to a University of Iowa study. The study ... but still have normal lung function, have very different blood ...
... Depression and schizophrenia can be triggered by environmental stimuli and ... some people have a higher predisposition to develop these diseases, ... disease risk. A high number of people with ... cells use to talk to each other in the brain. ...
Cached Biology News:Genetic key discovered to dramatically increase yields and improve taste of hybrid tomato plants 2Genetic key discovered to dramatically increase yields and improve taste of hybrid tomato plants 3New test could identify smokers at risk of emphysema 2Depression associated with sustained brain signals 2
MOUSE ANTI SIMIAN VIRUS 5:FITC Immunogen: Simian virus 5...
Collected from normal, healthy animals in carefully maintained standing herds of US orgin. Pricing: $45/unit for 1 - 10 units...
NORMAL DONOR DONKEY SERUM...
Whole blood is collected from canines (any breed, either sex), refrigerated within 6 hours, processed within 24 hours and frozen at -20C....
Biology Products: